Wall Street analysts forecast that Idera Pharmaceuticals Inc (NASDAQ:IDRA) will post sales of $130,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Idera Pharmaceuticals’ earnings. The highest sales estimate is $150,000.00 and the lowest is $100,000.00. Idera Pharmaceuticals reported sales of $260,000.00 in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The company is expected to announce its next quarterly earnings results on Wednesday, May 8th.

On average, analysts expect that Idera Pharmaceuticals will report full-year sales of $490,000.00 for the current year, with estimates ranging from $400,000.00 to $580,000.00. For the next fiscal year, analysts anticipate that the firm will report sales of $6.79 million, with estimates ranging from $420,000.00 to $13.15 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Idera Pharmaceuticals.

Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.06. Idera Pharmaceuticals had a negative return on equity of 75.10% and a negative net margin of 9,045.47%. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.12 million.

IDRA has been the topic of several recent research reports. HC Wainwright decreased their price target on Idera Pharmaceuticals to $14.00 and set a “buy” rating on the stock in a report on Friday, March 8th. Zacks Investment Research raised Idera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Thursday, March 7th. Finally, ValuEngine raised Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $16.71.

NASDAQ:IDRA traded up $0.20 during midday trading on Tuesday, hitting $2.57. 222,948 shares of the company traded hands, compared to its average volume of 328,508. Idera Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $17.12. The firm has a market capitalization of $70.98 million, a PE ratio of -1.13 and a beta of 2.55.

A number of institutional investors have recently made changes to their positions in IDRA. Virtu Financial LLC bought a new position in Idera Pharmaceuticals in the 4th quarter valued at $33,000. Jane Street Group LLC bought a new position in Idera Pharmaceuticals in the 4th quarter valued at $39,000. SG Americas Securities LLC bought a new position in Idera Pharmaceuticals in the 4th quarter valued at $41,000. Squarepoint Ops LLC grew its position in Idera Pharmaceuticals by 45.5% in the 4th quarter. Squarepoint Ops LLC now owns 18,900 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 5,910 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Idera Pharmaceuticals in the 4th quarter valued at $61,000. 44.71% of the stock is currently owned by institutional investors.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.

See Also: Understanding Options Trading

Get a free copy of the Zacks research report on Idera Pharmaceuticals (IDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.